| Entry |
|
|---|
| Name |
Olopatadine hydrochloride (JP17/USP);
Allelock (TN);
Patanol (TN);
Opatanol (TN)
|
|---|
| Product |
|
|---|
| Generic |
OLOPATADINE HYDROCHLORIDE (A-S Medication Solutions), OLOPATADINE (A-S Medication Solutions), OLOPATADINE (Akorn), OLOPATADINE (Akorn), OLOPATADINE HYDROCHLORIDE (Alembic Pharmaceuticals), OLOPATADINE HYDROCHLORIDE (Amneal Pharmaceuticals LLC), OLOPATADINE HYDROCHLORIDE (Apotex Corp.), OLOPATADINE HYDROCHLORIDE (Apotex Corp.), OLOPATADINE HYDROCHLORIDE (Apotex Corp.), OLOPATADINE HYDROCHLORIDE (Aurobindo Pharma Limited), OLOPATADINE HYDROCHLORIDE (Aurobindo Pharma Limited), OLOPATADINE HYDROCHLORIDE (Cipla USA), OLOPATADINE HYDROCHLORIDE (Direct Rx), OLOPATADINE HYDROCHLORIDE (ECI Pharmaceuticals), OLOPATADINE (Golden State Medical Supply), OLOPATADINE HYDROCHLORIDE (H.J. Harkins Company), OLOPATADINE HYDROCHLORIDE (Mylan Pharmaceuticals), OLOPATADINE HYDROCHLORIDE (NuCare Pharmaceuticals), OLOPATADINE HYDROCHLORIDE (Perrigo New York), OLOPATADINE HYDROCHLORIDE (Preferred Pharmaceuticals), OLOPATADINE HYDROCHLORIDE (Proficient Rx LP), OLOPATADINE HYDROCHLORIDE (Sandoz), OLOPATADINE HYDROCHLORIDE (Sandoz), OLOPATADINE HYDROCHLORIDE (Sandoz), OLOPATADINE HYDROCHLORIDE (Somerset Therapeutics), OLOPATADINE HYDROCHLORIDE (Teva Pharmaceuticals USA), OLOPATADINE HYDROCHLORIDE (Westminster Pharmaceuticals), OLOPATADINE HYDROCHLORIDE (Wockhardt USA LLC.), OLOPATADINE HYDROCHLORIDE (Cipla USA), OLOPATADINE HYDROCHLORIDE (Rising Pharmaceuticals) |
|---|
| Formula |
C21H23NO3. HCl
|
|---|
| Exact mass |
373.1445
|
|---|
| Mol weight |
373.8732
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
|
|---|
| Remark |
| Product (DG01039): | D01192<JP/US> |
|
|---|
| Efficacy |
Antiallergic, H1 receptor antagonist |
|---|
| Disease |
Seasonal allergic rhinitis [DS: H01360] |
|---|
| Comment |
Loratadine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07212 | Histamine H1 receptor antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R01 NASAL PREPARATIONS
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01AC Antiallergic agents, excl. corticosteroids
R01AC08 Olopatadine
D01192 Olopatadine hydrochloride (JP17/USP) <JP/US>
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01G DECONGESTANTS AND ANTIALLERGICS
S01GX Other antiallergics
S01GX09 Olopatadine
D01192 Olopatadine hydrochloride (JP17/USP) <JP/US>
USP drug classification [BR:br08302]
Ophthalmic Agents
Ophthalmic Anti-allergy Agents
Antihistamine
Olopatadine
D01192 Olopatadine hydrochloride (JP17/USP)
Respiratory Tract/Pulmonary Agents
Antihistamines
Histamine (H1) Receptor Antagonists, Mildly/Non-sedating
Olopatadine
D01192 Olopatadine hydrochloride (JP17/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D01192 Olopatadine hydrochloride (JP17/USP)
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D01192 Olopatadine hydrochloride (JP17/USP)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH1
D01192 Olopatadine hydrochloride (JP17/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01192 Olopatadine hydrochloride
D01192 Olopatadine hydrochloride tablets
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01192
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01192
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01192
Rx-to-OTC switch list in Japan [br08314.html]
D01192
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 26
1 X Cl 25.5488 -17.6013
2 O2x O 18.4771 -20.2698
3 C8y C 17.6355 -19.1476
4 C8y C 17.9161 -17.7450
5 C2y C 19.1785 -17.1839
6 C1x C 19.8798 -20.2698
7 C8y C 20.4409 -17.8151
8 C8y C 20.7214 -19.2178
9 C8x C 16.9341 -16.7630
10 C8y C 15.6016 -17.1839
11 C8x C 15.2509 -18.5165
12 C8x C 16.2328 -19.4983
13 C8x C 22.1241 -19.6385
14 C8x C 23.1060 -18.6567
15 C8x C 22.8254 -17.3241
16 C8x C 21.4929 -16.9034
17 C2b C 19.1785 -15.7812
18 C1b C 14.5495 -16.2021
19 C6a C 13.2170 -16.6228
20 O6a O 12.2351 -15.6410
21 O6a O 12.8664 -17.9554
22 C1b C 17.9865 -15.0638
23 C1b C 17.9865 -13.6646
24 N1c N 16.7747 -12.9650
25 C1a C 15.5841 -13.6522
26 C1a C 16.7746 -11.5441
BOND 27
1 4 5 1
2 2 6 1
3 5 7 1
4 3 4 1
5 6 8 1
6 2 3 1
7 7 8 1
8 4 9 2
9 9 10 1
10 10 11 2
11 11 12 1
12 3 12 2
13 8 13 2
14 13 14 1
15 14 15 2
16 15 16 1
17 7 16 2
18 5 17 2
19 10 18 1
20 18 19 1
21 19 20 1
22 19 21 2
23 17 22 1
24 22 23 1
25 23 24 1
26 24 25 1
27 24 26 1
|
|---|
|
